Broad spectrum Antimicrobial example
broad spectrum antimicrobials examples clinical pharmacology
| Drug | Coverage |
|---|---|
| Imipenem/Cilastatin | Gram+, Gram-, anaerobes, some ESBL-producers |
| Meropenem | Similar to imipenem; better CNS penetration |
| Ertapenem | Similar but lacks Pseudomonas/Acinetobacter coverage |
| Doripenem | Anti-pseudomonal, hospital use |
| Drug | Notes |
|---|---|
| Ampicillin | Classic broad-spectrum; active against Gram- organisms beyond penicillin G |
| Amoxicillin | Oral; similar to ampicillin |
| Piperacillin-Tazobactam (Pip-Tazo) | Extended spectrum including Pseudomonas + anaerobes |
| Ticarcillin-Clavulanate | Anti-pseudomonal |
| Generation | Examples | Coverage |
|---|---|---|
| 3rd Gen | Ceftriaxone, Cefotaxime, Ceftazidime | Broad Gram- coverage |
| 4th Gen | Cefepime | Gram+ and Gram-, including Pseudomonas |
| 5th Gen | Ceftaroline | MRSA + Gram- |
| Novel | Cefiderocol | Siderophore cephalosporin; covers MDR Gram- including carbapenem-resistant organisms |
| Drug | Key Use |
|---|---|
| Ciprofloxacin | Gram- focus; best anti-pseudomonal quinolone |
| Levofloxacin | Broad; excellent respiratory coverage ("respiratory quinolone") |
| Moxifloxacin | Broad; adds anaerobic coverage; no Pseudomonas |
| Drug | Notes |
|---|---|
| Doxycycline | Gram+, Gram-, atypicals, rickettsiae |
| Tetracycline | Classic; broad including chlamydiae |
| Minocycline | Also active against MRSA in some settings |
| Tigecycline | Glycylcycline; very broad including MRSA, VRE, and many MDR organisms |
| Drug | Notes |
|---|---|
| Gentamicin | Gram-negative bacilli including Pseudomonas |
| Tobramycin | Strong anti-pseudomonal |
| Amikacin | Broader resistance profile; reserved for MDR organisms |
| Streptomycin | TB + plague |
| Drug | Notes |
|---|---|
| Azithromycin | Gram+, atypicals (Mycoplasma, Chlamydia, Legionella), some Gram- |
| Clarithromycin | Similar; also H. pylori |
| Erythromycin | Classic, narrower than azithromycin |
| Class | Prototype Example | Gram+ | Gram- | Anaerobes | Atypicals |
|---|---|---|---|---|---|
| Carbapenems | Imipenem | ✓ | ✓✓ | ✓ | - |
| Extended Penicillins | Pip-Tazo | ✓ | ✓✓ | ✓ | - |
| 3rd/4th Gen Cephalosporins | Ceftriaxone, Cefepime | ✓ | ✓✓ | - | - |
| Fluoroquinolones | Ciprofloxacin | ✓ | ✓✓ | ± | ✓ |
| Tetracyclines | Doxycycline | ✓ | ✓ | - | ✓✓ |
| Chloramphenicol | Chloramphenicol | ✓ | ✓ | ✓ | ✓ |
| Aminoglycosides | Gentamicin | ± | ✓✓ | - | - |
| TMP-SMX | Co-trimoxazole | ✓ | ✓ | - | ✓ |
| Macrolides | Azithromycin | ✓ | ± | - | ✓✓ |
Stewardship note: Broad-spectrum use carries risks - disruption of normal flora, Clostridioides difficile infection (CDI), and selection of resistant organisms (e.g., MRSA, ESBL-producers, carbapenem-resistant Enterobacteriaceae). Harrison's Principles emphasizes de-escalation to narrow-spectrum targeted therapy once culture results are available.
Create a diagram
